PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15126378-7	2004	Celecoxib supplementation to TRAMP mice from 8-32 weeks of age exhibited significant reduction in tumor development (5 of 20) with no signs of metastasis.	Celecoxib	0-9	tumor necrosis factor receptor superfamily, member 25	Mus musculus	29-34	
30585351-9	2019	CONCLUSIONS: Celecoxib plus nintedanib is an effective antitumor combination against prostate cancer progression in TRAMP mice, showing remarkable efficacy in relation to isolated therapies.	Celecoxib	13-22	tumor necrosis factor receptor superfamily, member 25	Mus musculus	116-121	
30585351-11	2019	In addition, celecoxib and nintedanib impaired the development of a stromal reaction by reducing the recruitment of reactive stroma cells and maintaining a normal smooth muscle cell-rich prostate stroma in TRAMP mice.	Celecoxib	13-22	tumor necrosis factor receptor superfamily, member 25	Mus musculus	206-211	
20937024-10	2010	Genistein, alpha-difluoromethylornithine, toremifene, R-flurbiprofen, celecoxib, and green tea polyphenols have been shown to prevent prostate cancer development in TRAMP mice.	Celecoxib	70-79	tumor necrosis factor receptor superfamily, member 25	Mus musculus	165-170